Table 2:
Clinical Characteristics of Children Starting Antiretroviral Therapy in Mozambique during 2004–2009
| Original* | Imputed | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Median/%** | (IQR/95% CI) | Median or %** | (IQR/95% CI) | 2004 (n=18, 2%) | 2005 (n=62, 5%) | 2006 (n=162, 15%) | 2007 (n=326, 29%) | 2008 (n=289, 27%) | 2009* (n=197, 19%) | P-value | |
| TB treatment at ART start | ||||||||||||
| Yes | 163 | 15% | (7–22%) | 15% | (7–22%) | 31% | 25% | 15% | 16% | 13% | 10% | 0.093 |
| No | 887 | 85% | (78–93%) | 85% | (78–93%) | 69% | 75% | 85% | 84% | 87% | 90% | |
| Observations Missing Data | 4 | 0% | ||||||||||
| Prior TB | ||||||||||||
| Yes | 156 | 14% | (9–20%) | 14% | (9–20%) | 50% | 22% | 14% | 16% | 12% | 10% | 0.009 |
| No | 894 | 86% | (80–91%) | 86% | (80–91%) | 50% | 78% | 86% | 84% | 88% | 90% | |
| Observations missing data | 4 | 0% | ||||||||||
| Prior Pneumonia | ||||||||||||
| Yes | 221 | 19% | (12–26%) | 19% | (12–26%) | 65% | 24% | 19% | 22% | 15% | 14% | 0.015 |
| No | 829 | 81% | (74–88%) | 81% | (74–88%) | 35% | 76% | 81% | 78% | 85% | 86% | |
| Observations missing data | 4 | 0% | ||||||||||
| Prior PCP | ||||||||||||
| Yes | 16 | 1% | (1–2%) | 2% | (1–2%) | 5% | 3% | 2% | 2% | 2% | 1% | 0.252 |
| No | 1034 | 99% | (98–99%) | 98% | (98–99%) | 95% | 97% | 98% | 98% | 98% | 99% | |
| Observations missing data | 4 | 0% | ||||||||||
| Prior Lymphocytic Interstitial Pneumonia | ||||||||||||
| Yes | 48 | 4% | (0–8%) | 4% | (0–8%) | 16% | 13% | 9% | 3% | 2% | 1% | <0.001 |
| No | 1002 | 96% | (92–100%) | 96% | (92–100%) | 84% | 87% | 91% | 97% | 98% | 99% | |
| Observations missing data | 4 | 0% | ||||||||||
| Maternal ARVs Received During Pregnancy/Delivery | ||||||||||||
| Yes | 83 | 13% | (10–16%) | 17% | (12–22%) | 11% | 6% | 9% | 13% | 14% | 36% | 0.009 |
| No | 613 | 87% | (84–90%) | 83% | (78–88%) | 89% | 94% | 91% | 87% | 86% | 64% | |
| Observations missing data | 358 | 34% | ||||||||||
| Infant exposure to PMTCT ARVs after birth | ||||||||||||
| Yes | 35 | 5% | (3–8%) | 9% | (5–14%) | 4% | 2% | 4% | 7% | 9% | 17% | 0.028 |
| No | 696 | 95% | (92–98%) | 91% | (86–95%) | 96% | 98% | 96% | 93% | 91% | 83% | |
| Missing | 323 | 31% | ||||||||||
| Weight-for-Age Z-score (Median) | ||||||||||||
| Both Sexes | 888 | −2.1 | (−3.3– −1.1) | −2.1 | (−3.3– −1.1) | −1.8 | −1.8 | −2.4 | −2.3 | −2.1 | −1.8 | 0.594 |
| Observations missing data | 166 | 16% | ||||||||||
| Weight-for-Height Z-score (Median) | ||||||||||||
| Both Sexes | 635 | −0.7 | (−2– 0.4) | −0.7 | (−2.1– 0.5) | 0.4 | 0.04 | −0.5 | −0.9 | −0.7 | −0.9 | 0.347 |
| Observations missing data | 419 | 40% | ||||||||||
| CD4 cell % (Median) | ||||||||||||
| All ages | 766 | 12.6 | (7.9–17.9) | 13 | (8–18) | 10 | 13 | 12 | 13 | 13 | 13 | 0.935 |
| Observations missing data | 288 | 27% | ||||||||||
| CD4 cell count (Median) | ||||||||||||
| All ages | 791 | 382 | (111–652) | 375 | (97–652) | 204 | 406 | 380 | 400 | 396 | 307 | 0.871 |
| Observations missing data | 263 | 25% | ||||||||||
| Hemoglobin | ||||||||||||
| All ages | 798 | 9.5 | (8.5–10.4) | 9.5 | (8.4–10.5) | 9.9 | 9.9 | 9.6 | 9.6 | 9.4 | 9.5 | 0.248 |
| Observations missing data | 256 | 24.3 | ||||||||||
| Alanine Aminotransferase Categories (ALT) | ||||||||||||
| Normal (≤56/uL) | 618 | 88% | (84–91%) | 83% | (78–88%) | 93% | 91% | 88% | 87% | 77% | 79% | 0.098 |
| Moderately abnormal (57–100/uL) | 32 | 5% | (3–8%) | 9% | (6–13%) | 5% | 7% | 7% | 7% | 12% | 11% | |
| Abnormal (>100/uL) | 43 | 7% | (4–10%) | 8% | (5–11%) | 2% | 2% | 6% | 6% | 12% | 9% | |
| Observations missing data | 361 | 34% | ||||||||||
| CTX prescription | ||||||||||||
| Yes | 305 | 48% | (28–68%) | 42% | (29–56%) | 54% | 42% | 41% | 46% | 38% | 42% | 0.684 |
| No | 345 | 52% | (32–72%) | 58% | (44–71%) | 46% | 58% | 59% | 54% | 62% | 58% | |
| observations missing data | 404 | 38% | ||||||||||
Abbreviations: IQR, inter-quartile range; CI, confidence interval; TB, tuberculosis; PMTCT, prevention of mother-to-child transmission; ARVs, antiretrovirals; CTX, co-trimoxazole; PCP, Pneumocystis jirovecii pneumonia; ART, antiretroviral therapy
*
The denominator used to estimate percentages presented in the original data columns was 1,054 minus the number of observations missing data.
**
All proportions and medians presented in this table are weighted to account for survey design.